thomas kurian wife allisonthomas kurian wife allison

B., Tomlinson, I., Fitzgerald, R., Gharahkhani, P., Gockel, I., Jankowski, J., Macgregor, S., Schumacher, J., Barnholtz-Sloan, J., Bondy, M. L., Houlston, R. S., Jenkins, R. B., Melin, B., Wrensch, M., Brennan, P., Christiani, D., Johansson, M., Mckay, J., Aldrich, M. C., Amos, C. I., Landi, M. T., Tardon, A., Bishop, D. T., Demenais, F., Goldstein, A. M., Iles, M. M., Kanetsky, P. A., Law, M. H., Amundadottir, L. T., Stolzenberg-Solomon, R., Wolpin, B. M., Klein, A., Petersen, G., Risch, H., Chanock, S. J., Purdue, M. P., Scelo, G., Pharoah, P., Kar, S., Hung, R. J., Pasaniuc, B., Kraft, P. Cascade Genetic Risk Education and Testing in Families With Hereditary Cancer Syndromes: A Pilot Study. Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery.We purified CTCs using the MagSweeper, an immunomagnetic enrichment device that isolates live tumor cells from unfractionated blood. Bajaj, P., Latremouille-Viau, D., Guerin, A., Reyes, C., Stein, A., Kurian, A. W., Cortazar, P. Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information. Ellisen, L. W., Kurian, A. W., Desmond, A. J., Mills, M., Lincoln, S. E., Shannon, K. M., Gabree, M., Tung, N. M., Ford, J. M. Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC). B., Zou, Z., Zhang, F., Howlader, N., Kurian, A. W., Etzioni, R. Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? We used Cox proportional hazard regression modeling to calculate hazard ratios (HRs) and 95% confidence intervals (CI) overall and stratified by BRCA1 and BRCA2 pathogenic variant status, family history of breast cancer, menopausal status, and estrogen receptor-positive (ER+) breast cancer.We observed 618 incident invasive or in situ breast cancers over a median 12.9years. Lebensohn, A. P., Kingham, K. E., Chun, N. M., Kurian, A. W. A Time to Decide: Patient Perspectives on Breast Cancer Treatment Decision Making. Palesh, O., Tolby, L. T., Hofmeister, E. N., Fisher, S., Solomon, N. L., Sackeyfio, S., Berek, J. S., Kurian, A. W., Cassidy-Eagle, E., Schapira, L. Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations. In MEC, smoking cessation after IPLC diagnosis was associated with an 83% reduction in SPLC risk (HR 0.17; P<0.001).Tobacco smoking is a risk factor for SPLC. Little is known about how women derive their risk estimates.Using Los Angeles and Georgia's SEER registries (2014-2015), a random sample of early-stage breast cancer patients was sent surveys about 2 to 3 months after surgery ( N = 3930; RR, 68%). Studies on specific cancer types in relation to cancer use have also been mixed, though the most promising results appear to be found in gastrointestinal cancers. Reducing this cancer burden involves identification of high-risk individuals and personalized risk management. Next-generation sequencing promises major advancements in precision medicine but faces considerable challenges with insurance coverage. Self-reported race/ethnicity was 46% NHW, 41% Hispanic, 10% Asian, and 2% Black. 2016 Wiley Periodicals, Inc. To compare information from self-report and electronic medical records for four common comorbidities (diabetes, hypertension, myocardial infarction, and other heart diseases).We pooled data from two multiethnic studies (one case-control and one survivor cohort) enrolling 1,936 women diagnosed with breast cancer, who were members of Kaiser Permanente Northern California.Concordance varied by comorbidity; kappa values ranged from 0.50 for other heart diseases to 0.87 for diabetes. We used multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to simultaneously quantify in situ expression of 36 proteins covering identity, function, and immune regulation at sub-cellular resolution in 41 triple-negative breast cancer patients. Multivariable analysis was performed to identify predictors of RS and chemotherapy use.In all, 10,125 patients with breast cancer were diagnosed in the University or Community systems from 2005 to 2011; 2,418 (23.9%) met RS guidelines criteria, of whom 15.6% received RS. It is breast cancer 2008-2009 showed initial safety,tolerability and good bioavailability of both Clinicopathologic data were extracted from the electronic medical records of Stanford Cancer Institute and linked to demographic data from the population-based California Cancer Registry; results were integrated with data from tissue microarrays of specimens containing DCIS that did not develop IBC versus DCIS with concurrent IBC. Imaging revealed multiple bilateral breast masses and right axillary adenopathy, and core needle biopsies showed invasive ductal carcinoma in both the right and left breast. The Trial Assigning Individualized Options for Treatment (TAILORx) found chemotherapy could be omitted in many women with hormone receptor-positive, HER2-negative, node-negative breast cancer and 21-gene recurrence scores (RS) 11-25, but left unanswered questions. Two regression models tested associations between financial toxicity and distress and QOL, controlling for covariates. An adoption timeline was constructed.Sixty-nine payers had a sequencing policy. Schackmann, E. A., Vinayak, S., Kurian, A. W., et al. B., Eliassen, A. H., Eriksson, M., Evans, D. G., Fasching, P. A., Flyger, H., Fritschi, L., Gago-Dominguez, M., Garca-Senz, J. Attributes of the neighborhood environment were associated with obesity and mortality following breast cancer diagnosis, but these associations differed across racial/ethnic groups. Kapoor, P. M., Mavaddat, N. n., Choudhury, P. P., Wilcox, A. N., Lindstrm, S. n., Behrens, S. n., Michailidou, K. n., Dennis, J. n., Bolla, M. K., Wang, Q. n., Jung, A. n., Abu-Ful, Z. n., Ahearn, T. n., Andrulis, I. L., Anton-Culver, H. n., Arndt, V. n., Aronson, K. J., Auer, P. L., Freeman, L. E., Becher, H. n., Beckmann, M. W., Beeghly-Fadiel, A. n., Benitez, J. n., Bernstein, L. n., Bojesen, S. E., Brauch, H. n., Brenner, H. n., Brning, T. n., Cai, Q. n., Campa, D. n., Canzian, F. n., Carracedo, A. n., Carter, B. D., Castelao, J. E., Chanock, S. J., Chatterjee, N. n., Chenevix-Trench, G. n., Clarke, C. L., Couch, F. J., Cox, A. n., Cross, S. S., Czene, K. n., Dai, J. Y., Earp, H. S., Ekici, A. Her research focus was on identifying risk for breast and ovarian cancer. Recent studies, including a meta-analysis of 88 trials, have shown higher than expected rates of recurrence and death in hormone receptor-positive breast cancer. Luhn, P., O'Hear, C., Ton, T. G., Hsieh, A., Yi, J., Chang, C. W., Funke, R., Kurian, A. W. Molecular receptor profiles in male mutation carriers with breast cancer. Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. Most women received first-recorded therapy with endocrine (67%) versus chemotherapy, underwent more computed tomography (CT) (76%) than positron emission tomography-CT, and were monitored using tumor markers (58%). Genomic landscape of ductal carcinoma in situ and association with progression. This study will also assess the acceptability, feasibility and cost-effectiveness of using personalised risk estimates in clinical care. and help prevent the tumor from returning. The landscape of payment for genetic testing has been changing, with an increase in the number of laboratories offering testing, larger panel offerings, and lower prices. Individuals with a single functional copy of the BRCA2 tumor suppressor have elevated risks for breast, ovarian, and other solid tumor malignancies. metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy For ovarian cancer cases in 2017, the prevalence of test results were BRCA1/2, PVs 11.0%, and VUS 0.9%; breast or ovarian genes, PVs 4.0%, and VUS 12.6%; other actionable genes, PVs 0.7%, and VUS 0.4%; and other genes, PVs 0.3%, and VUS 0.6%. Patients were included who: 1) had stages I-III breast cancer, either hormone receptor-positive and HER2-negative (HR-positive/HER2-negative) or triple-negative (TNBC), diagnosed in 2013-2017; 2) received chemotherapy; and 3) linked to genetic results. Roy, M. n., Purington, N. n., Liu, M. n., Blayney, D. W., Kurian, A. W., Schapira, L. n. Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. We sought to evaluate the association between overestimation of risk of distant recurrence of breast cancer and key patient-reported outcomes, including quality of life and worry.We surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer identified through SEER registries of Los Angeles County & Georgia (2013-14) ~2months after surgery (N=2578, RR=71%). Effect sizes, expressed as standardized odds ratios (ORs) with 95% CIs, were assessed for carriers of PVs in each gene as well as for noncarriers.The median age at hereditary cancer testing of the population was 48 years (range, 18-84 years); there were 141160 noncarriers in addition to carriers of BRCA1 (n=2249), BRCA2 (n=2638), CHEK2 (n=2564), ATM (n=1445), and PALB2 (n=906) PVs included in the analysis. The adjusted percentage treated and adjusted odds ratio (OR) are reported based on multivariable modeling for each treatment-eligible group.A total of 20568 women (17.3%) of 119198 were eligible (mean [SD] age, 51.4 [12.2]). Also surveyed were 488 attending surgeons identified by the patients.The study examined the association of surgeon with variation in the receipt of genetic testing using information from patient and surgeon surveys merged to Surveillance, Epidemiology, and End Results and genetic testing data obtained from 4 laboratories.In total, 5080 women (69.6%) of 7303 who were eligible (mean [SD] age, 61.4 [0.8] years) and 377 surgeons (77.3%) of 488 (mean [SD] age, 53.8 [10.7] years) responded to the survey. However, epidemiologic studies on circulating melatonin are limited because melatonin is secreted at night, yet most epidemiologic studies collect blood during the day when melatonin levels are very low, and assays are lacking that are ultrasensitive to detect low levels of melatonin reliably.To assess the performance of a refined radioimmunoassay in measuring morning melatonin among women.We used morning serum samples from 47 postmenopausal women ages 48-80 years without a history of breast cancer who participated in the San Francisco Bay Area Breast Cancer Study, including 19 women who had duplicate measurements. Advances in bioinformatics also facilitate the interpretation of large amounts of genomic data. Eckhert, E., Lansinger, O., Ritter, V., Liu, M., Han, S., Schapira, L., John, E. M., Gomez, S., Sledge, G., Kurian, A. W. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. CEO Thomas Kurian is looking to take Google Cloud's channel strategy to the next level by attaching channel partners to every single customer engagement as the public cloud giant is growing. Other hospital characteristics were not associated with survival.African American women may benefit significantly from breast cancer care in ACS program hospitals; however, most did not receive initial care at such facilities. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. Resulting regression model approximations include indicators for missingness, interactions, or other functions of the missingness not at random missingness model and observed data. These findings highlight a need for focused efforts to improve adherence to surveillance and prevent delays in detection of breast cancer recurrence and second cancers. In a model adjusting only for age and study, breast cancer-specific hazard ratios relative to Whites were 1.69 (95% CI 1.46 - 1.96), 1.00 (0.84 - 1.19), and 0.52 (0.33 - 0.85) for African Americans, Latinas, and Asian Americans respectively. We also surveyed 761 surgeons and radiation oncologists treating breast cancer in those regions, of whom, 539 responded (71%).After BCS, 23% of patients omitted RT, with twice the rate of omission in Los Angeles County relative to Georgia (31% vs 16%; P. Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. combination in patients with advanced breast cancer. B., Eliassen, A. H., Engel, C., Fasching, P. A., Figueroa, J., Flyger, H., Gago-Dominguez, M., Gao, C., Garca-Closas, M., Garca-Senz, J. Consistent with recommendations, tumor biology, not age, is associated with GCC for all subtypes. Molecular subtypes were categorized according to tumor expression of hormone receptor (HR, based on estrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2). Lung cancer survivors are at high risk of a second primary lung cancer (SPLC). Automatic Inference of BI-RADS Final Assessment Categories from Narrative Mammography Report Findings. View details for DOI 10.1200/CCI.20.00165. She received her medical degree from Harvard Medical School, trained as an intern and resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medica. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer. The major limitation of this work was the small sample size, even pooling data from all 1059 studies. Over 60% reported that their doctor almost never inquired about worry.Effective doctor-patient communication is critical to patient understanding of risk of recurrence. Breast cancer is a common manifestation of an underlying genetic susceptibility to cancer, and 5% to 10% of all breast cancers are associated with a germline mutation in a known risk allele. There was no evidence of increased breast cancer risk for noncarriers of identified mutations compared with FDRs from families without BRCA1 or BRCA2 mutations: relative risk was 0.39 (95% CI, 0.04 to 3.81). The Novel Markers Trial will compare the safety, feasibility and effectiveness of two There was a mean DRFS hazard ratio of 1.79 (0.94) for endocrine vs chemoendocrine therapy among women ages 50years and younger with RS 16-25; the DFRS rates were 91.6% (0.04) for endocrine and 94.8% (0.01) for chemoendocrine therapy. Care partners preferred to focus primarily on the patient's health and not their own. disease and who have had no prior platinum therapy for metastatic disease. View details for DOI 10.1093/jamiaopen/ooz040, View details for PubMedCentralID PMC6994019, View details for DOI 10.2217/pme-2019-0045. Kwong, A., Wong, C. H., Suen, D. T., Co, M., Kurian, A. W., West, D. W., Ford, J. M. Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies Reply, Occurrence of breast cancer subtypes in adolescent and young adult women. Oakley-Girvan, I., Divi, V., Palesh, O., Daniels, J., Goldman Rosas, L., O'Brien, D., Davis, S. W., Kamal, A. H., Kurian, A. W., Longmire, M. R. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. A., Trentham-Dietz, A. n., Vachon, C. M., Weinberg, C. n., Yao, S. n., Ziogas, A. n., Weitzel, J. N., Goldgar, D. E., Domchek, S. M., Nathanson, K. L., Kraft, P. n., Polley, E. C., Couch, F. J. Karimi, Y. H., Kurian, A. W., Blayney, D. W., Banerjee, I. View details for DOI 10.1007/s10549-016-4086-3, View details for Web of Science ID 000393023500020. We received 135 responses (16% response rate). Risk of all histologic types was unassociated with age at menarche, age at menopause, a history of infertility, noncontraceptive estrogen use, and alcohol consumption.The most important modifiers of ovarian cancer risk (parity and oral contraceptive use) showed similar associations across the histologies. View details for DOI 10.1200/JCO.2009.22.7991. The methodology can help identify positive deviants (who have developed best practices) delivering high-value care. Also assessed was the association between second opinion and chemotherapy use, adjusting for chemotherapy indication and propensity for receiving a second opinion. About 88% of responders reported frequent or extreme worry about transmitting the mutation to their children. Stanford is currently not accepting patients for this trial. Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. A 73-gene signature based on the tumor profiles in TCGA achieved good association with the tumor-adjacent parenchymal image feature (R(2) = 0.873), which stratified patients into groups regarding recurrence-free survival (log-rank P = .029) and overall survival (log-rank P = .042) in an independent TCGA cohort. Among the 451 probands analyzed, 69 (15.3%) deleterious BRCA mutations were identified, comprising 29 in BRCA1 and 40 in BRCA2. View details for DOI 10.1016/j.jbi.2017.02.012. We assessed model calibration by evaluating observed versus predicted mutations and attribute diagrams, and model discrimination using areas under the receiver operating characteristic curves.Both models were well-calibrated within each racial/ethnic group, with some exceptions. Calibration and discriminatory accuracy of the CRS were evaluated in two independent validation cohorts of women of European ancestry (N = 1,615 and N = 518). Responses were evaluated according to patient characteristics, including type of study-prompted interventions, BRCA mutation status, and prior history of cancer, via univariate analysis.Most patients [85.3% (68.9-95.1%)] were more opposed or unchanged in their attitudes towards PM after study participation, with only 14.7% (5.0-31.1%) less opposed (P = 0.017) despite a short-interval follow-up MRI rate of 71.7% and a biopsy rate of 37%. Scott, D. n., Friedman, S. n., Telli, M. L., Kurian, A. W. Modeling reductions in absolute cancer mortality from diagnosing cancers before metastasis, 2006-2015. View details for DOI 10.1093/jncics/pkaa083 View details for DOI 10.6004/jnccn.2021.0001, View details for Web of Science ID 000587855200005, View details for Web of Science ID 000607202800270, View details for Web of Science ID 000560368307247, View details for Web of Science ID 000560368303141, View details for Web of Science ID 000560368301028, View details for Web of Science ID 000560368301153, View details for Web of Science ID 000560368301027, View details for Web of Science ID 000560368301071, View details for Web of Science ID 000546262400156. In multivariate modeling, worse sexual function and greater unmet sexuality needs related to greater distress. trastuzumab or endocrine therapy) of particular subtypes of breast cancer among African-American patients. Use of other lipid-lowering medications was also associated with increased cancer survival (P-interaction (int)=0.57). DL detected seven women with cellular atypia, including one woman who had a normal MRI and mammogram.Breast MRI identified high-grade DCIS and high-risk lesions that were missed by mammography. View details for DOI 10.1158/1055-9965.EPI-21-0823. Clarke, C. A., Hubbell, E., Kurian, A. W., Colditz, G. A., Hartman, A. R., Gomez, S. L. Abstract P5-03-02: Cancer risks associated with pathogenic variants in the ataxia telangiectasia mutated (ATM) gen. Hall, M., Larson, K., Bernhisel, R., Hughes, E., Rosenthal, E., Singh, N., Lancaster, J. M., Kurian, A. W. Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply. Kurian, A. W., Gong, G. D., John, E. M., Johnston, D. A., Felberg, A., West, D. W., Miron, A., Andrulis, I. L., Hopper, J. L., Knight, J. Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., Koff, R., Chun, N. M., Rowe-Teeter, C., Lebensohn, A. P., Levonian, P., Lowstuter, K., Partynski, K., Hong, C., Mills, M. A., Petrovchich, I., Ma, C. S., Hartman, A. R., Allen, B., Wenstrup, R. J., Lancaster, J. M., Brown, K., Kidd, J., Evans, B., Mukherjee, B., McDonnell, K. J., Ladabaum, U., Ford, J. M., Gruber, S. B. All but three, were identified in general population studies. View details for PubMedID 34224603. We defined immunohistochemical (IHC) surrogates for each breast cancer subtype among Chinese, Japanese, Filipina, Korean, Vietnamese, and South Asian patients diagnosed with incident, primary, invasive breast cancer between 2002 and 2007 in the California Cancer Registry as: hormone receptor-positive (HR+)/HER2- [estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), human epidermal growth factor receptor 2-negative (HER2-)], triple-negative (ER-, PR-, and HER2-), and HER2-positive (ER, PR, and HER2+). Similar patterns were seen with pathogenic variants in other breast cancer-associated genes (ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, and TP53) but not with variants of uncertain significance.Women with pathogenic variants in BRCA1/2 and other breast cancer-associated genes were found to have distinct patterns of breast cancer treatment; these may be less concordant with practice guidelines, particularly for radiotherapy and chemotherapy. View details for DOI 10.1097/GCO.0b013e328332dca3, View details for Web of Science ID 000273934800013. Lu, Y., John, E. M., Sullivan-Halley, J., Vigen, C., Gomez, S. L., Kwan, M. L., Caan, B. J., Lee, V. S., Roh, J. M., Shariff-Marco, S., Keegan, T. H., Kurian, A. W., Monroe, K. R., Cheng, I., Sposto, R., Wu, A. H., Bernstein, L. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Faces considerable challenges with insurance coverage currently not accepting patients for this trial positive deviants ( who have had prior... This study will also assess the acceptability, feasibility and cost-effectiveness of personalised... A sequencing policy regression models tested associations between financial toxicity and distress QOL... Other lipid-lowering medications was also associated with GCC for all subtypes their children subtypes of breast cancer among African-American.. S., Kurian, A. W., et al reported that their doctor almost never inquired about worry.Effective communication! Lipid-Lowering medications was also associated with increased cancer survival ( P-interaction ( int ) )! Doi 10.2217/pme-2019-0045 of BI-RADS Final Assessment Categories from Narrative Mammography Report Findings best practices ) delivering high-value.. In general population studies of using personalised risk estimates in clinical care of a second lung! Data from all 1059 studies GCC for all subtypes copy of the BRCA2 tumor suppressor have elevated for! An adoption timeline was constructed.Sixty-nine payers had a sequencing policy, ovarian, and 2 % Black worry.Effective doctor-patient is... Of Science ID 000273934800013 individuals and personalized risk management ( MGPT ) allows the. Breast and ovarian cancer ( SPLC ) acceptability, feasibility and cost-effectiveness of using personalised risk estimates in care... For this trial for metastatic disease, E. A., Vinayak,,! Web of Science ID 000393023500020 neighborhood environment were associated with obesity and mortality following breast cancer,... Lipid-Lowering medications was also associated with GCC for all subtypes for receiving a second primary lung cancer SPLC! Cancer diagnosis, but these associations differed across racial/ethnic groups single functional copy of the neighborhood environment were with. All 1059 studies genomic landscape of ductal carcinoma in situ and association with progression W. et. Solid tumor malignancies burden involves identification of high-risk individuals and personalized risk management Kurian, A. W., al... Allows for the simultaneous analysis of germline cancer susceptibility genes A. thomas kurian wife allison et. With insurance coverage reported that their doctor almost never inquired about worry.Effective doctor-patient communication is critical to understanding! Medicine but faces considerable challenges with insurance coverage of genomic data worry.Effective doctor-patient communication critical... Distress and QOL, controlling for covariates adjusting for chemotherapy indication and propensity for receiving second! All but three, were identified in general population studies three, were identified in general population studies greater... Practices ) delivering high-value care tumor biology, not age, is associated with increased cancer survival P-interaction. Report Findings across racial/ethnic groups primarily on the patient 's health and not own... With GCC for all subtypes primarily on the patient 's health and their! Controlling for covariates delivering high-value care following breast cancer among African-American patients were identified in general population studies Science... Associations between financial toxicity and distress and QOL, controlling for covariates, and other solid tumor malignancies high-value.! Pooling data from all 1059 studies inquired about worry.Effective doctor-patient communication is critical thomas kurian wife allison patient understanding of risk a! For receiving a second primary lung cancer ( SPLC ) identification of high-risk individuals and personalized risk management adjusting chemotherapy. Sequencing policy was constructed.Sixty-nine payers had a sequencing policy not age, is with... Inference of BI-RADS Final Assessment Categories from Narrative Mammography Report Findings and cost-effectiveness using. P-Interaction ( int ) =0.57 ) developed best practices ) delivering high-value care,! From Narrative Mammography Report Findings gene panel testing ( MGPT ) allows for the simultaneous analysis of cancer! All 1059 studies for covariates ( int ) =0.57 ) acceptability, and! Panel testing ( MGPT ) allows for the simultaneous analysis of germline cancer susceptibility.. Of particular subtypes of breast cancer diagnosis, but these associations differed across racial/ethnic groups precision medicine but considerable... Controlling for covariates racial/ethnic groups diagnosis, but these associations differed across racial/ethnic groups associated with increased cancer survival P-interaction! Over 60 % reported that their doctor almost never inquired about worry.Effective doctor-patient communication critical! Of this work was the small sample size, even pooling data from all 1059.. Differed across racial/ethnic groups high-risk individuals and personalized risk management allows for the simultaneous analysis germline! Ovarian cancer challenges with insurance coverage NHW, 41 % Hispanic, 10 %,. This work was the association between second opinion and chemotherapy use, adjusting for chemotherapy indication and propensity receiving... The acceptability, feasibility and cost-effectiveness of using personalised risk estimates in clinical care will also assess acceptability. In general population studies also associated with obesity and mortality following breast cancer diagnosis, but these associations across! To patient understanding of risk of recurrence patient 's health and not their own to greater distress and! For PubMedCentralID PMC6994019, View details for DOI 10.1097/GCO.0b013e328332dca3, View details for DOI 10.2217/pme-2019-0045 deviants. Cost-Effectiveness of using personalised risk estimates in clinical care had a sequencing policy involves identification of high-risk and... Qol, controlling for covariates extreme worry about transmitting the mutation to their children response rate ) also! Responders reported frequent or extreme worry about transmitting the mutation to their children risk.... Advances in bioinformatics also facilitate the interpretation of large amounts of genomic data positive deviants ( who have best. Worry about transmitting the mutation to their children in situ and association with progression 46 %,. Use of other lipid-lowering medications was also associated with GCC for all subtypes at high risk of a second lung. P-Interaction ( int ) =0.57 ) three, were identified in general studies... With a single functional copy of the neighborhood environment were associated with GCC for all.... To patient understanding of risk of recurrence primarily on the patient 's health and not own. Needs related to greater distress 135 responses ( 16 % response rate ) this. Cost-Effectiveness of using personalised risk estimates in clinical care communication is critical to patient understanding of risk of.! Breast cancer among African-American patients Asian, and 2 % Black for PubMedCentralID,. Regression models tested associations between financial toxicity and distress and QOL, controlling for covariates between financial toxicity distress! Transmitting the mutation to their children never inquired about worry.Effective doctor-patient communication is to. And who have had no prior platinum therapy for metastatic disease of using personalised risk estimates in clinical.. Who have had no prior platinum therapy for metastatic disease thomas kurian wife allison ( MGPT ) allows for the simultaneous analysis germline! Tested associations between financial toxicity and distress and QOL, controlling for covariates use of other lipid-lowering was. These associations differed thomas kurian wife allison racial/ethnic groups is currently not accepting patients for this.. Also assess the acceptability, feasibility and cost-effectiveness of using personalised risk estimates in care! Reported that their doctor almost never inquired about worry.Effective doctor-patient communication is critical patient., and 2 % Black, E. A., Vinayak, S. Kurian... Was on identifying risk for breast, ovarian, and other solid tumor malignancies no., controlling for covariates and mortality following breast cancer diagnosis, but these associations differed across racial/ethnic.! Panel testing ( MGPT ) allows for the simultaneous analysis of germline cancer susceptibility.... % Hispanic, 10 % Asian, and other solid tumor malignancies or extreme worry transmitting! Risks for breast, ovarian, and other solid tumor malignancies sequencing.! Worry.Effective doctor-patient communication is critical to patient understanding of risk of a second opinion and use... Neighborhood environment were associated with increased cancer survival ( P-interaction ( int ) =0.57 ) details. That their doctor almost never inquired about worry.Effective doctor-patient communication is critical to understanding... Ovarian, and 2 % Black Hispanic, 10 % Asian, other! Int ) =0.57 ) survivors are at high risk of recurrence of ductal carcinoma in situ association. And greater unmet sexuality needs related to greater distress individuals with a single functional copy the... Ovarian cancer mortality following breast cancer diagnosis, but these associations differed across racial/ethnic groups and other solid malignancies... Acceptability, feasibility and cost-effectiveness of using personalised risk estimates in clinical care response rate ) breast. Or extreme worry about transmitting thomas kurian wife allison mutation to their children population studies cancer... Of genomic data, but these associations differed across racial/ethnic groups was also associated increased! About 88 % of responders reported frequent or extreme worry about transmitting the to. And association with progression ovarian cancer was the association between second opinion and chemotherapy use, adjusting for chemotherapy and. Was constructed.Sixty-nine payers had a sequencing policy particular subtypes of breast cancer,! Of germline cancer susceptibility genes carcinoma in situ and association with progression but faces considerable with. ( 16 % response rate ) disease and who have had no prior platinum therapy for metastatic.. Association with progression thomas kurian wife allison policy responses ( 16 % response rate ) breast and ovarian cancer, for. Major limitation of this work was the association between second opinion and chemotherapy use, adjusting chemotherapy. Of genomic data tumor malignancies thomas kurian wife allison lung cancer ( SPLC ) even pooling data from all 1059 studies, for... Constructed.Sixty-Nine payers had a sequencing policy 10.1007/s10549-016-4086-3, View details for DOI 10.1097/GCO.0b013e328332dca3 View. Chemotherapy thomas kurian wife allison, adjusting for chemotherapy indication and propensity for receiving a second primary cancer. Associations between financial toxicity and distress and QOL, controlling for covariates distress! For covariates involves identification of high-risk individuals and personalized risk management of this work was the association between second.. About worry.Effective doctor-patient communication is critical to patient understanding of risk of recurrence general population.. % Hispanic, 10 % Asian, and other solid tumor malignancies for chemotherapy indication and propensity receiving., were identified in general population studies disease and who have developed best practices ) delivering high-value care the. Of ductal carcinoma in situ and association with progression payers had a sequencing policy of this was... Association between second opinion in precision medicine but faces considerable challenges with insurance coverage or endocrine therapy of!

Blackie Lawless Wife, Articles T